2018 American Society of Hematology Annual Meeting*

December 1-4, 2018; San Diego, California
Review slidesets and analyses of key data from the 2018 Hematology meeting.


Capsule Summary Slidesets

Investigational anti-CD33 antibody–drug conjugate with a novel mechanism of action demonstrated preliminary antileukemia activity and tolerability in dose-escalation study.

Released: December 3, 2018

Nearly all patients who received sequential HCVAD with blinatumomab achieved MRD-negative status.

Released: December 4, 2018

Frontline blinatumomab with POMP maintenance was well tolerated with no early deaths in this cohort of patients aged 65 years or older.

Released: December 3, 2018

Early results show addition of blinatumomab to inotuzumab ozogamicin plus mini-HCVD efficacious in older patients with newly diagnosed Ph- ALL.

Released: December 3, 2018

Nonrandomized, observational study suggests reduced event-free survival in patients receiving generic vs branded imatinib.

Released: December 5, 2018

Venetoclax with HMA active and tolerable in hard-to-treat elderly AML patients.

Released: December 5, 2018

Long-term OS benefit was observed in patients with Ph-negative ALL, particularly those who achieved complete MRD response after the first cycle of blinatumomab or while in first CR

Released: December 7, 2018

In patients with newly diagnosed AML with IDH1 or IDH2 mutations, addition of ivosidenib or enasidenib to standard chemotherapy was associated with good tolerability, mutation clearance, and MRD negativity.

Released: December 18, 2018

In patients with R/R FLT3-ITD–mutated AML, single-agent quizartinib significantly prolongs survival compared with salvage chemotherapy with a low incidence of grade 3 QT prolongation.

Released: December 17, 2018

Combination of the FLT3 inhibitor gilteritinib with standard intensive chemotherapy was active and tolerable as first-line AML therapy.

Released: December 5, 2018

Sorafenib maintenance therapy after transplantation significantly reduced the disease relapse rate and improved survival compared with placebo in patients with FLT3-ITD AML.

Released: December 10, 2018
Provided by the Annenberg Center for Health Sciences at Eisenhower.

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?